* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Gene Section KIAA1199 (KIAA1199) Atlas of Genetics and Cytogenetics in Oncology and Haematology
Designer baby wikipedia , lookup
Epigenetics in learning and memory wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Long non-coding RNA wikipedia , lookup
Gene expression profiling wikipedia , lookup
Genome (book) wikipedia , lookup
Epigenetics of diabetes Type 2 wikipedia , lookup
Epigenetics of human development wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Protein moonlighting wikipedia , lookup
Gene therapy of the human retina wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Cancer epigenetics wikipedia , lookup
Point mutation wikipedia , lookup
Polycomb Group Proteins and Cancer wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Therapeutic gene modulation wikipedia , lookup
Secreted frizzled-related protein 1 wikipedia , lookup
Oncogenomics wikipedia , lookup
Atlas of Genetics and Cytogenetics in Oncology and Haematology INIST-CNRS OPEN ACCESS JOURNAL Gene Section Short Communication KIAA1199 (KIAA1199) Nikki Ann Evensen, Cem Kuscu, Jian Cao Stony Brook University, Stony Brook, New York, USA (NAE, CK, JC) Published in Atlas Database: October 2013 Online updated version : http://AtlasGeneticsOncology.org/Genes/KIAA1199ID51053ch15q25.html DOI: 10.4267/2042/53643 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2014 Atlas of Genetics and Cytogenetics in Oncology and Haematology Other names: CCSP1, TMEM2L HGNC (Hugo): KIAA1199 Location: 15q25.1 Note Reported in the Human Unidentified Gene-Encoded Large Proteins (HUGE) database as KIAA1199. introns. The transcriptional start site is within the second exon. There is a canonical TATA-box present in the KIAA1199 promoter region at -31 to -27 base pairs, as well as a GC-box at -248 to -243 base pairs. However, this GC-box was not found to be required for transcriptional activation of KIAA1199, nor was there any methylation of the cytosines found within this region, which is often an important feature of GC-boxes. KIAA1199 also contains a CpG island within the first intron (+525 50 +1025). The methylation status of this CpG island was found to effect the expression level of KIAA1199, with high levels of DNA methylation found in non-aggressive, low expressing, cancer cell lines (Kuscu et al., 2012). DNA/RNA Transcription Abstract Review on KIAA1199, with data on DNA/RNA, on the protein encoded and where the gene is implicated. Identity An AP-1 binding site, located between -48 and -45 within the KIAA1199 promoter, was found to be important for KIAA1199 promoter activity. AP-1 was found to directly bind to this region in order to activate transcription of KIAA1199. Description The human KIAA1199 transcript spans 7080 base pairs on chromosome 15 in the region 15q25.1. It contains 29 exons, 28 of which are coding, and 28 Atlas Genet Cytogenet Oncol Haematol. 2014; 18(5) 324 KIAA1199 (KIAA1199) Evensen NA, et al. AP-1 transcription factors have been associated with increased promoter activity of genes associated with cancer. Additionally, among four potential NF-κB binding sites, the site furthest from the transcriptional start site (-1345 to -1333) was found to play a role in KIAA1199 promoter activation. NF-κB was found to directly bind to this site to increase transcription of KIAA1199 (Kuscu et al., 2012). (BiP)/glucose-regulated protein (GRP-78), which further supports the ER localization of KIAA1199 (Evensen et al., 2013). Secretion of KIAA1199 has also been demonstrated for certain cell types (Tiwari et al., 2013). Function KIAA1199 plays a key role in cancer progression via increasing cancer cell migration and invasion, which are necessary steps for cancer metastasis. Expression of KIAA1199 in non-aggressive cancer cell lines leads to an epithelial-to-mesenchymal transition along with increased migratory capabilites. Furthermore, knockdown of KIAA1199 leads to a loss of mesenchymal characteristics with decreased invasive and migratory abilities, as well as reduced metastastic potential (Evensen et al., 2013). A role for KIAA1199 in maintaining ion homeostasis, and more specifically calcium signaling, has also been suggested (Abe et al., 2003; Tiwari et al., 2013). KIAA1199-mediated migration was found to involve elevated cytosolic calcium levels followed by protein kinase C alpha (PKCα) translocation/activation. This change in cytosolic calcium is due to increased release of calcium from the ER via an unknown mechanism induced by KIAA1199 (Evensen et al., 2013). Additional studies revealed an interaction with KIAA1199 and inositol 1,4,5-triphosphate receptor 3 (ITPR3) which is a ligand-gated ion channel located on the ER membrane that is known to mediate the release of calcium from the ER (Tiwari et al., 2013). KIAA1199 is thought to be a target of the Wnt signaling pathway and a potential player in the progression of colorectal adenomatous (SabatesBellver et al., 2007; Tiwari et al., 2013). Additionally, silencing of KIAA1199 was shown to alter the expression of genes known to be involved in the Wnt/β-catenin pathway and decrease cell proliferation (Birkenkamp-Demtroder et al., 2011). In human skin fibroblasts, KIAA1199 expression was found to cause increased degradation of hyaluronan (HA), which is a glycosaminoglycan found in the extracellular matrix surrounding tissues. It acts as a structural component and can affect cell signaling and cellular behavior, including angiogenesis and cell migration (Yoshida et al., 2013). Protein Description The KIAA1199 open reading frame consists of 4083 base pairs, which encodes a protein 1361 amino acids in length. It has a predicted molecular weight of approximately 163 kDa. The KIAA1199 protein has a G8 domain between a.a. 44-166, which is a novel domain that contains eight conserved glycines and consists of five β-strand pairs (He et al., 2006). Several disease related proteins contain this domain, including polyductin protein (PKHD1) and transmembrane protein 2 (TMEM2), although the exact function of the G8 motif remains unclear (He et al., 2006). A GG domain, characterized by seven β-strands and two α-helices, can also be found within the KIAA1199 protein (Guo et al., 2006). This novel domain also has no known function. KIAA1199 is also predicted to have a cleavable signal peptide at its NH2terminus (Sabates-Bellver et al., 2007). KIAA1199 has been demonstrated to be N-linked glycosylated (Tiwari et al., 2013). Expression Northern blot analysis of normal human tissues revealed expression of KIAA1199 mRNA in various tissues, with the highest levels found in the brain, placenta, lung, and testis (Michishita et al., 2006). KIAA1199 is also expressed in various cell types found in the inner ear (Abe et al., 2003; Usami et al., 2008), and in dermal fibroblasts of the skin (Yoshida et al., 2013). Increased levels of KIAA1199 have also been demonstrated in numerous cancer tissues compared to normal tissues, including colorectal adenomas (SabatesBellver et al., 2007). Localisation Cytoplasmic and nuclear staining for KIAA1199 has been observed in gastric and colon cancer tissue samples (Sabates-Bellver et al., 2007; Matsuzaki et al., 2009; Birkenkamp-Demtroder et al., 2011). More detailed subcellular localization revealed expression of exogenous and endogenous KIAA1199 within the endoplasmic reticulum (ER) of various cell types (Evensen et al., 2013; Tiwari et al., 2013). KIAA1199 was found to interact with the ER chaperone binding immunoglobulin protein Atlas Genet Cytogenet Oncol Haematol. 2014; 18(5) Homology The KIAA1199 gene product shares 38% identity (63% similarity) with transmembrane protein 2 (TMEM2). A small region within the KIAA1199 gene product (aa 55-155) also shares 38% identity (57% similarity) with polyductin protein (PKHD1) (Abe et al., 2003). However, none of these homologies revealed any functional information. 325 KIAA1199 (KIAA1199) Evensen NA, et al. Mutations non-syndromic hearing loss diseases. FEBS Lett. 2006 Jan 23;580(2):581-4 Somatic He QY, Liu XH, Li Q, Studholme DJ, Li XW, Liang SP. G8: a novel domain associated with polycystic kidney disease and non-syndromic hearing loss. Bioinformatics. 2006 Sep 15;22(18):2189-91 Nine DNA variants of the KIAA1199 gene were identified, six of which were missense (R187C, R187H, H783R, H783Y, V1109I, and P1169A) and three of which were synonymous substitutions (L532L, P619P, D800D). R187C, R187H, H783Y, and V1109I were found only in families with nonsyndromic hearing loss, suggesting a potential role for these specific mutations in this disease state (Abe et al., 2003). Michishita E, Garcés G, Barrett JC, Horikawa I. Upregulation of the KIAA1199 gene is associated with cellular mortality. Cancer Lett. 2006 Jul 28;239(1):71-7 Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H, Laczko E, Kurowski MA, Bujnicki JM, Menigatti M, Luz J, Ranalli TV, Gomes V, Pastorelli A, Faggiani R, Anti M, Jiricny J, Clevers H, Marra G. Transcriptome profile of human colorectal adenomas. Mol Cancer Res. 2007 Dec;5(12):1263-75 Implicated in Usami S, Takumi Y, Suzuki N, Oguchi T, Oshima A, Suzuki H, Kitoh R, Abe S, Sasaki A, Matsubara A. The localization of proteins encoded by CRYM, KIAA1199, UBA52, COL9A3, and COL9A1, genes highly expressed in the cochlea. Neuroscience. 2008 Jun 12;154(1):22-8 Gastric and colorectal cancers Prognosis Numerous studies have implicated KIAA1199 expression with cancer progression. Gastric cancer patients with low expression of KIAA1199 were found to have significantly better overall 5-year survival rates as compared to those expressing higher levels. Furthermore, lymph node metastasis, distant metastasis, and peritoneal dissemination were more often observed in the patients with higher levels of KIAA1199 (Matsuzaki et al., 2009). Additionally, there is evidence to suggest that KIAA1199 could potentially be used as a biomarker for cancer. Higher levels of KIAA1199 transcripts were found in the serum of patients with adenoma and colorectal cancer as compared to neoplasia free controls (LaPointe et al., 2012). KIAA1199 was also found to be upregulated in cancerous tissues from gastric adenocarcinoma patients, further supporting the idea of using KIAA1199 for diagnostics, early detection, or as a predictor of cancer progression (Chivu Economescu et al., 2010). Matsuzaki S, Tanaka F, Mimori K, Tahara K, Inoue H, Mori M. Clinicopathologic significance of KIAA1199 overexpression in human gastric cancer. Ann Surg Oncol. 2009 Jul;16(7):2042-51 Chivu Economescu M, Necula LG, Dragu D, Badea L, Dima SO, Tudor S, Nastase A, Popescu I, Diaconu CC. Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection. Hepatogastroenterology. 2010 Nov-Dec;57(104):1453-64 Birkenkamp-Demtroder K, Maghnouj A, Mansilla F, Thorsen K, Andersen CL, Øster B, Hahn S, Ørntoft TF. Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells. Br J Cancer. 2011 Aug 9;105(4):552-61 Kuscu C, Evensen N, Kim D, Hu YJ, Zucker S, Cao J. Transcriptional and epigenetic regulation of KIAA1199 gene expression in human breast cancer. PLoS One. 2012;7(9):e44661 LaPointe LC, Pedersen SK, Dunne R, Brown GS, Pimlott L, Gaur S, McEvoy A, Thomas M, Wattchow D, Molloy PL, Young GP. Discovery and validation of molecular biomarkers for colorectal adenomas and cancer with application to blood testing. PLoS One. 2012;7(1):e29059 Evensen NA, Kuscu C, Nguyen HL, Zarrabi K, Dufour A, Kadam P, Hu YJ, Pulkoski-Gross A, Bahou WF, Zucker S, Cao J. Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration. J Natl Cancer Inst. 2013 Sep 18;105(18):1402-16 Nonsyndromic hearing loss Prognosis Several mutations within KIAA1199 were found in patients with nonsyndromic hearing loss but not in control subjects. Based on the expression pattern of KIAA1199 in the cells of the inner ear, it is thought that it could play a role in normal auditory development with these particular mutations having a negative impact (Abe et al., 2003). Tiwari A, Schneider M, Fiorino A, Haider R, Okoniewski MJ, Roschitzki B, Uzozie A, Menigatti M, Jiricny J, Marra G. Early insights into the function of KIAA1199, a markedly overexpressed protein in human colorectal tumors. PLoS One. 2013;8(7):e69473 Yoshida H, Nagaoka A, Kusaka-Kikushima A, Tobiishi M, Kawabata K, Sayo T, Sakai S, Sugiyama Y, Enomoto H, Okada Y, Inoue S. KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding protein involved in hyaluronan depolymerization. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5612-7 References Abe S, Usami S, Nakamura Y. Mutations in the gene encoding KIAA1199 protein, an inner-ear protein expressed in Deiters' cells and the fibrocytes, as the cause of nonsyndromic hearing loss. J Hum Genet. 2003;48(11):564-70 This article should be referenced as such: Evensen NA, Kuscu C, Cao J. KIAA1199 (KIAA1199). Atlas Genet Cytogenet Oncol Haematol. 2014; 18(5):324326. Guo J, Cheng H, Zhao S, Yu L. GG: a domain involved in phage LTF apparatus and implicated in human MEB and Atlas Genet Cytogenet Oncol Haematol. 2014; 18(5) 326